RE:RE:One thing shareholders wantedI'd say they didn't quite have enough start-up/biotech RD types on the Board (they mostly all came and are still from large pharma). This is all hindsight analysis, but clearly not raising $100-$150mil on the Trogarzo sales bump in the share price was a massive mistake for which we and the company are all paying for. When you get a huge surprise jump in your shareprice, almost every biotech and biotech banker will tell you to take advantage of it with equity, not debt. Luc and co did not have the proper marketing study around Trogarzo and mistakenly believed those market share numbers (although, so did the market until it hit the fan). It's all hindsight, so easy to see now, but by way of comparison, a few of those biotechs that got caught up in the Gamestop frenzy immediately raised boatloads of capital that will fund everything they ever wanted to. The difference was they were startups and had venture cap guys on their Boards. THTX should have had that skill plugged in instead of large Montreal pharma types. Anway, water under the bridge -- we're in cost cutting, 9% rev growth territory and hope around a PDC working better. Baring that, maybe they surprise us with a new product add-in and then enough POC to convince someone to partner in the areas they've pushed further in like immuno, anti-metastatic, etc... We'll see by end of year, but that was the Luc/Board mistake, for better or for worse.